Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
121 studies found for:    "Leiomyosarcoma"
Show Display Options
Rank Status Study
1 Completed Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma
Conditions: Uterus Leiomyosarcoma;   Soft Tissue Leiomyosarcoma
Interventions: Drug: Doxorubicin;   Drug: Trabectedin
2 Completed Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma;   Uterine Neoplasm
Intervention: Drug: gemcitabine, docetaxel, doxorubicin
3 Active, not recruiting Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
Conditions: Leiomyosarcoma;   Uterine Neoplasm
Intervention: Drug: Letrozole
4 Recruiting Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
Condition: Leiomyosarcoma
Interventions: Drug: gemcitabine + docetaxel;   Drug: trabectedin
5 Recruiting Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Conditions: Liposarcoma;   Leiomyosarcoma
Intervention: Drug: Trabectedin
6 Not yet recruiting Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas
Condition: Leiomyosarcoma
Intervention: Drug: pazopanib + gemcitabine
7 Recruiting A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Condition: Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin;   Drug: Dacarbazine
8 Active, not recruiting A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin;   Drug: Dacarbazine
9 Recruiting Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Condition: Relapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas
Interventions: Drug: Pazopanib plus Gemcitabine;   Drug: Pazopanib
10 Completed
Has Results
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Condition: Leiomyosarcoma
Intervention: Drug: letrozole
11 Active, not recruiting Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions: Recurrent Uterine Sarcoma;   Uterine Leiomyosarcoma
Interventions: Drug: alisertib;   Other: laboratory biomarker analysis
12 Completed Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Conditions: Uterine Leiomyosarcoma;   Uterine Cancer
Intervention: Drug: Docetaxel plus Gemcitabine
13 Completed Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions: Recurrent Uterine Sarcoma;   Uterine Leiomyosarcoma
Intervention: Drug: sunitinib malate
14 Active, not recruiting Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Conditions: Recurrent Uterine Sarcoma;   Uterine Leiomyosarcoma
Interventions: Other: diagnostic laboratory biomarker analysis;   Drug: ixabepilone
15 Recruiting Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma;   Uterine Leiomyosarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Other: clinical observation
16 Active, not recruiting Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Conditions: Recurrent Uterine Corpus Sarcoma;   Stage IIIA Uterine Sarcoma;   Stage IIIB Uterine Sarcoma;   Stage IIIC Uterine Sarcoma;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Other: Placebo;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Drug: Docetaxel;   Biological: Filgrastim;   Biological: Pegfilgrastim
17 Unknown  Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Conditions: Leiomyosarcoma;   Liposarcoma
Intervention: Drug: Gemcitabine + Trabectedin
18 Completed
Has Results
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Conditions: Liposarcoma;   Leiomyosarcoma
Interventions: Drug: Yondelis;   Drug: Dexamethasone
19 Completed Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Conditions: Recurrent Uterine Sarcoma;   Uterine Leiomyosarcoma
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
20 Completed Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Conditions: Recurrent Uterine Sarcoma;   Uterine Leiomyosarcoma
Interventions: Drug: gemcitabine hydrochloride;   Drug: docetaxel;   Biological: filgrastim;   Biological: pegfilgrastim

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years